Utilizing a unique discovery platform of cancer vaccines, based on decades of basic research by a distinguished lead pioneer in immuno therapy, Precision Biologics has developed several monoclonal antibodies (“mAbs”). The company is conducting studies examining these antibodies as Therapeutics and as companion diagnostic biomarkers for our ongoing clinical programs. Preliminary results have been presented at key scientific conferences.

Our leading mAb candidate currently in product development-referred to as Ensituximab or NPC-1C (NEO-102)-is one that recognizes a particular epitope of tumor specific antigens (“TSAs”) from pancreatic/colorectal adenocarcinoma. The Precision Biologics antibody is being developed as a therapeutic drug candidate for pancreatic and colorectal cancers and as companion diagnostic using patient’s tumor tissue for immunohistochemistry (IHC) for the detection of NEO-102 target on colon and pancreatic cancers.

The company has completed a Phase 2 clinical trial with NEO-102 treating patients with advanced metastatic colorectal cancer. This multicenter trial enrolled patients at several highly prestigious academic medical centers in the US.

We are also completing data analysis of a multi-center randomized Phase 2 clinical study with NEO-102 in combination with 2nd line chemotherapy, treating patients with metastatic pancreatic cancer.

Our 2nd AB candidate clinical stage compound, NEO-201, is currently enrolling patients with refractory solid tumors in a Phase I clinical trial at the National Cancer Institute. This first in human study is designed to treat individuals with chemotherapy refractory tumors including colorectal, pancreatic, non small cell lung cancer (NSCLC), breast cancer, as well as mucinous ovarian cancer.

Precision Biologics has a 3rd preclinical candidate NEO-301 (31.1). It binds to tumor specific antigens found in pancreatic, colorectal and several other types of cancer

With its proprietary library of Hollinshead cancer vaccines, antigens and antibodies, Precision Biologics is expanding its collaborations to identify further preclinical candidates that are tumor and disease specific.